tolvaptan has been researched along with aspirin in 3 studies
| Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (aspirin) | Trials (aspirin) | Recent Studies (post-2010) (aspirin) |
|---|---|---|---|---|---|
| 967 | 172 | 786 | 48,947 | 6,817 | 13,778 |
| Protein | Taxonomy | tolvaptan (IC50) | aspirin (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.35 | |
| Integrin beta-3 | Homo sapiens (human) | 5 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.8252 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 1.375 | |
| Integrin alpha-IIb | Homo sapiens (human) | 5 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.271 | |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | 2.4 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 2.15 | |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 0.3 | |
| 4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | 2.4 | |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.35 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.4081 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Tsukada, YT | 1 |
1 review(s) available for tolvaptan and aspirin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for tolvaptan and aspirin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Adverse effects of cardiovascular agents in Japan--update 2012].
Topics: Anticoagulants; Antidiuretic Hormone Receptor Antagonists; Aspirin; Benzazepines; Cardiovascular Agents; Drug Combinations; Embolism; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Hypernatremia; Japan; Platelet Aggregation Inhibitors; Substance Withdrawal Syndrome; Tolvaptan | 2012 |